Role of anti‐domain 1‐β2glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome
Essentials Antibodies to domain 1 of β2 glycoprotein I (aD1) are a subset of antiphospholipid antibodies. We evaluated the added diagnostic value of an automated aD1 assay in antiphospholipid syndrome. AD1 IgG correctly classifies patients at risk for thrombosis. Agreement between aD1 and aβ2GPI IgG...
Gespeichert in:
Veröffentlicht in: | Journal of thrombosis and haemostasis 2016-09, Vol.14 (9), p.1779-1787 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Essentials
Antibodies to domain 1 of β2 glycoprotein I (aD1) are a subset of antiphospholipid antibodies.
We evaluated the added diagnostic value of an automated aD1 assay in antiphospholipid syndrome.
AD1 IgG correctly classifies patients at risk for thrombosis.
Agreement between aD1 and aβ2GPI IgG is high, limiting the added value of aD1 in our setting.
Click to hear Professor de Groot's perspective on new mechanistic understanding in antiphospholipid syndrome
Summary
Background
Laboratory diagnosis of antiphospholipid syndrome (APS) includes lupus anticoagulant (LAC), anticardiolipin (aCL) or anti‐β2 glycoprotein I (aβ2GPI) antibodies. Antibodies targeting domain 1 of β2GPI (aD1) constitute a pathogenic subset of autoantibodies.
Objectives
In this cohort study, we determined the clinical performance characteristics, additional diagnostic value and the contribution to APS risk stratification of an automated aD1 assay.
Patients/Methods
LAC, aCL, aβ2GPI and aD1 IgG were measured in 101 APS patients, 123 patients with autoimmune disorders, 82 diseased controls and 120 healthy controls. aD1 antibodies were detected by QUANTA Flash® Beta2GPI‐Domain 1 chemiluminescence immunoassay.
Results
With a cut‐off value of 20.0 CU, the aD1 IgG assay identifies APS patients in a clinically affected patient cohort with a sensitivity of 53.5% and specificity of 98.8%. It implied a high odds ratio (OR) for clinical events (OR, 17.0; 95% confidence interval [CI], 7.1–40.5). aD1 IgG did not add diagnostic value to the formal aPL panel because aβ2GPI IgG was nearly as specific but more sensitive for APS (sensitivity 56.4%) with a higher OR for clinical events (36.2; 95% CI, 11.1–117.9). High aD1 titers identify triple‐positive patients and patients with thrombosis in a β2GPI‐dependent LAC‐positive population. Agreement between aD1 IgG and aβ2GPI IgG was high (positive and negative agreement 91.7% and 98.4%, respectively).
Conclusion
Detection of aD1 IgG correctly classifies patients at risk of thrombosis. However, the contribution of aD1 IgG to APS diagnosis and risk stratification depends upon the solid phase assays used for aCL and aβ2GPI detection. |
---|---|
ISSN: | 1538-7933 1538-7836 1538-7836 |
DOI: | 10.1111/jth.13389 |